Overexpression of LAPTM4B-35 closely correlated with clinicopathological features and post-resectional survival of gallbladder carcinoma

Zhou, Li; He, Xiaodong; Chen, Jie; Cui, Quancai; Qu, Qiang; Rui, Jing‐An; Zhao, Yupei

doi:10.1016/j.ejca.2006.10.025

Cited by 56 publications

(35 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8 Liu et al found that LAPTM4B-35 was highly associated with the differentiation of HCC and with gallbladder carcinoma. 5,6,9,14 In addition, Abbreviations: OR, odds ratio; CI, confidence interval.…”

Section: Discussionmentioning

confidence: 99%

LAPTM4B overexpression is a novel predictor of epithelial ovarian carcinoma metastasis

Yin

Lou

et al. 2010

Intl Journal of Cancer

View full text Add to dashboard Cite

LAPTM4B is a novel tumor-associated gene. To date, there have been no published data regarding the role of LAPTM4B expression in epithelial ovarian carcinoma metastasis. Therefore, this study was performed to determine whether LAPTM4B overexpression is a new predictor of epithelial ovarian carcinoma metastasis. LAPTM4B expression was evaluated in 22 normal ovarian specimens and 139 ovarian carcinomas by western blotting analyses and immunohistochemistry. Univariate and multivariate analyses were used to determine the association between LAPTM4B expression and epithelial ovarian carcinoma metastasis. Western blotting analysis demonstrated that LAPTM4B was overexpressed in metastatic tissues from patients with ovarian cancers, and immunohistochemistry results revealed that among 59 patients with LAPTM4B overexpression, 57 (96.6%) presented intraperitoneal metastasis and 31 (52.5%) had lymph node metastasis. The results of the univariate and multivariate analyses demonstrated that LAPTM4B overexpression correlated with metastasis. The odds ratio of high-to-low expression for intraperitoneal metastasis was 11.410 (95% CI: 2.357, 55.239) and that for lymph node metastasis was 6.332 (95% CI: 2.533, 15.831). For intraperitoneal metastasis, the sensitivity and specificity of LAPTM4B overexpression were 48.7% and 90.9%; for lymph node metastasis, they were 73.8%% and 71.1%, respectively. LAPTM4B overexpression is a new predictor of epithelial ovarian carcinoma metastasis and an important potential biomarker for the early diagnosis of ovarian carcinoma.Ovarian carcinoma is the leading cause of death among gynecologic cancers.1 Epithelial ovarian carcinomas (EOC) account for almost 90% of all ovarian cancers. Because of a lack of early screening tools and effective biomarkers for the general population, the majority of patients with EOC present with widely intraperitoneal and/or lymph node metastatic disease at diagnosis.2 Despite primary surgical cytoreduction and systematic administration of chemotherapy regimens, the 5-year survival rate for patients with advanced disease remains below 20%.3,4 Therefore, there is a critical need to find effective biomarkers for ovarian carcinoma metastasis that could predict the progression of advanced ovarian carcinoma and provide targets for chemoprevention.Lysosome-associated protein transmembrane-4 beta (LAPTM4B), a novel tumor-associated gene, has been successfully cloned in hepatocellular carcinomas HCCs. 5,6 It is highly overexpressed in a variety of human tumors, exhibiting the strongest expression levels in the ovary and uterus. 7These results strongly indicated that LAPTM4B might play important roles in the initiation, promotion and metastasis of tumors.8 In addition, positive expression was found to occur more often in tumors with progressive and invasive phenotypes, a low differentiation grade, and the presence of lymph node and perineural invasion.9,10 Thus, the LAPTM4B gene potentially could be used as a new predictor for metastasis in ovarian carcinomas.To date, there hav...

show abstract

Section: Discussionmentioning

confidence: 99%

LAPTM4B overexpression is a novel predictor of epithelial ovarian carcinoma metastasis

Yin

Lou

et al. 2010

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…According to BLAST program analysis, it is located in chromosomes 8q22 and is composed of seven exons separated by six introns (6,7). It was previously reported that LAPTM4B protein was markedly overexpressed in various malignant tumors, including pancreatic (8), gallbladder (9), ovarian (10) and cervical cancer (11). Two alleles of the LAPTM4B gene have been recognized, designated as LAPTM4B*1 and LAPTM4B*2 (GenBank nos.…”

Section: Introductionmentioning

confidence: 99%

LAPTM4B polymorphism is associated with non-small cell lung cancer susceptibility and prognosis

et al. 2014

View full text Add to dashboard Cite

Abstract. Lysosome-associated protein transmembrane-4β (LAPTM4B) is a novel cancer-related gene that is upregulated in many tumors, and which plays important roles in carcinogenesis. It has two alleles, LAPTM4B*1 and LAPTM4B*2. LAPTM4B*1 contains only one copy of a 19-bp sequence in the first exon, whereas LAPTM4B*2 contains two tight tandem segments. Previous studies have shown that LAPTM4B*2 is a risk factor for susceptibility and prognosis of many tumors. The present study investigated the relationship between LAPTM4B polymorphism and non-small cell lung cancer (NSCLC) susceptibility and prognosis. We identified LAPTM4B genotypes with polymerase chain reaction (PCR) in peripheral blood samples. In the adjusted multivariate logistic regression analysis, we found that LAPTM4B*1/2, LAPTM4B*2/2 exhibited 1.48-fold [95% confidence interval (CI), 1.076-2.037] and 2.855-fold (95%CI, 1.722-4.734) increases in the risk of developing NSCLC compared with non-LAPTM4B*2 carriers. Furthermore, our results showed that overall survival time and disease-free survival time of patients with LAPTM4B*2 were significantly shorter than in patients carrying LAPTM4B*1 (P=0.001 and P=0.001, respectively). In addition, multivariate Cox regression analysis revealed that LAPTM4B*2 was also an independent prognostic factor for NSCLC. These results suggest that LAPTM4B polymorphisms may be a prospective marker for evaluating the risk and prognosis of NSCLC.

show abstract

“…It could promote the proliferation of tumor cells, boost invasion and metastasis, resist apoptosis, initiate autophagy and assist drug resistance [4]. In addition, overexpression of LAPTM4B was significantly correlated with poor prognosis in breast cancer [5], gallbladder cancer [6,7], ovarian cancer [8], HCC [9][10][11], gastric cancer [12] and cervical cancer [13] LAPTM4B gene has two alleles named LAPTM4B*1 and LAPTM4B*2 (GenBank numbers AY219176 and AY219177, respectively). Allele *1 contains only one copy of a 19-bp sequence at the 5'UTR in the first exon, whereas the sequence in allele *2 is duplicated and tandemly repeated [14].…”

Section: Introductionmentioning

confidence: 99%

The Transcription Factor AP4 Promotes Oncogenic Phenotypes and Cisplatin Resistance by Regulating LAPTM4B Expression

Wang

Yue

et al. 2018

Molecular Cancer Research

View full text Add to dashboard Cite

Lysosomal-associated protein transmembrane-4 beta (LAPTM4B) is a novel oncogene, whose overexpression is involved in cancer occurrence and progression.However, the mechanism of LAPTM4B transcriptional regulation remains unclear. In this study, the results of transcription factor (TF) profiling plate arrays indicated that AP4 was a potential transcription factor regulating LAPTM4B expression. LAPTM4B was positively correlated with AP4 and they were both associated with poor overall and disease-free survival. Luciferase and EMSA assays confirmed that AP4 directly bound to the polymorphism region of LAPTM4B promoter and modulated its transcription. Functionally, AP4 promoted cell proliferation, migration, invasion and assisted drug resistance in part through up-regulation of LAPTM4B. Taken together, Implications: This study demonstrates that AP4 promotes cell growth, migration, invasion and cisplatin resistance through up-regulation of LAPTM4B expression, thus representing an attractive therapeutic target for breast cancer.

show abstract

Overexpression of LAPTM4B-35 closely correlated with clinicopathological features and post-resectional survival of gallbladder carcinoma

Cited by 56 publications

References 21 publications

LAPTM4B overexpression is a novel predictor of epithelial ovarian carcinoma metastasis

LAPTM4B overexpression is a novel predictor of epithelial ovarian carcinoma metastasis

LAPTM4B polymorphism is associated with non-small cell lung cancer susceptibility and prognosis

The Transcription Factor AP4 Promotes Oncogenic Phenotypes and Cisplatin Resistance by Regulating LAPTM4B Expression

Contact Info

Product

Resources

About